![]() |
|
|
Forward to a colleague |
||
Access Full Stories Celgene has agreed to pay $2.9bn for Pharmion in the hope of becoming a 'global leader in the haematology and oncology field', but do the company's pipelines match up well together?... Read Pfizer saves Coley with $164m buyout After a clinical hiccough five months ago set Coley Pharmaceutical's drug development funding back several years, Pfizer has stepped in to save the day, snapping up the biotech for $164m... Read APIcross goes solo in drug delivery Contract pharmaceutical development company Azopharma has carved out its drug delivery segment into a new company, APIcross Drug Delivery Technologies... Read J&J Belgium suffers strike over job cuts Workers at Johnson & Johnson's (J&J's) Belgium subsidiary went on strike today in protest at the compensation being offered to those at the firm falling foul of the dreaded pharma axe... Read NeoMPS gets acquired PolyPeptide Laboratories Group is to acquire the peptide manufacturing group NeoMPS... Read |
||||||||||||||
All News Headlines for: November | October | September |
||||||||||||||
Upgrading pharmaceutical production with new bulk excipients Are you looking for a new bulk excipient to facilitate wet granulation or compaction? The new galenIQ™ 800 series offers tailor-made powder grades to upgrade your agglomeration process... Click Here | ||||||||||||||
|
Related Industry News Caliper launches combo drug testing services Caliper Life Sciences has launched new testing services that will help researchers weed out unsuitable combination drug therapies in the preclinic... Read Russia's clinical biz showing signs of recovery after biologics ban Russia's clinical trials industry appears to be making a gradual recovery from a setback earlier this year when the government imposed an unexpected ban on biologic exports... Read Celesio sees profits drag Celesio fingerpointed two 'extraordinary items' in its dominant Wholesale division for the drag on company profits during the third quarter... Read Stem cell breakthrough avoids the embryo controversy US researchers have developed a way of creating primate embryonic stem cells that avoids the need to use fertilised embryos, potentially leading to more ethical ways of curing degenerative diseases... Read
|
||||||||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@In-PharmaTechnologist.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||